PharmaVoice
JUNE 24, 2024
With a career focused on striking deals, Kaan Cartel is hoping to lead the Flagship-backed biotech with an mRNA platform into its next phase of growth.
Drug Topics
JUNE 24, 2024
Discover how regulatory advancements are shaping the future of pharmacy automation. Our white paper explores the collaborative efforts between industry leaders and regulatory bodies, highlighting the pivotal role of regulations in advancing pharmacy practices. Learn how automation, including robotics and intelligent software, can enhance pharmacist efficiency and patient care.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JUNE 24, 2024
Shahida Choudhry, PharmD, shares her journey in pharmacy ownership.
Drug Topics
JUNE 24, 2024
See what’s trending in pharmacy with a preview of the Total Pharmacy June issue.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
STAT
JUNE 24, 2024
Bird flu snapshot: This is the second installment in a series of regular updates on H5N1 avian flu that STAT is publishing on Monday mornings. To read future updates you can also subscribe to STAT’s Morning Rounds newsletter. As the H5N1 outbreak in dairy herds approaches the three-month mark, America’s top animal health official is calling on farmers to step up the use of personal protective equipment, limit traffic onto their farms, and increase cleaning and disinfection practice
Drug Topics
JUNE 24, 2024
Check out these top featured stories from Drug Topics in June 2024.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Drug Topics
JUNE 24, 2024
A study found that having a high level of melanoma knowledge was significantly correlated with having risk factors for the disease, such as skin ultraviolet radiation vulnerability and lighter hair color.
Fierce Healthcare
JUNE 24, 2024
The Department of Health and Human Services (HHS) is locking in its enforcement strategy to keep healthcare providers from blocking access to electronic health information. | Providers found to have committed information blocking will face financial repercussions tied to Medicare program participation as well as the public disclosure of the enforcement.
Drug Topics
JUNE 24, 2024
Don’t miss out on the latest pharmacy insights in the Drug Topics June issue.
Pharmacy Times
JUNE 24, 2024
This case highlights the legal principle of premises liability
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
JUNE 24, 2024
The can’t-miss event on July 13 features speakers and CE sessions focused on streamlining pharmacy finances and services.
STAT
JUNE 24, 2024
WASHINGTON — He hardly seems the part of the telehealth industry’s public enemy No. 1. He’s unassuming, self-effacing, soft-spoken, with the bearing of a professor. But as telehealth lobbyists seize on this moment years after pandemic lockdowns to win new protections and incentives from Capitol Hill, Ateev Mehrotra is the industry’s chief critic — determined to warn congressional committees that the booming virtual care business comes with tradeoffs.
pharmaphorum
JUNE 24, 2024
Explore how digital twins are transforming healthcare and drug discovery, with success stories showcasing their impact in the biopharma industry. Learn about their journey from concept to real-world applications.
STAT
JUNE 24, 2024
When a new medical device hits the market, there’s typically still some uncertainty about whether it works. Device makers generally do not have to submit as much, or as rigorous, clinical data to the Food and Drug Administration as their biotech counterparts. Once FDA regulators decide a device is safe and effective, companies and researchers then attempt to track how the device performs in the real world.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Fierce Healthcare
JUNE 24, 2024
Higher care costs directly following a hospital merger have a downstream effect of local employers laying off a portion of their workers, according to a new National Bureau of Economic Researc | A new analysis ties merger-driven hospital price increases to higher employer insurance premiums and subsequent headcount reductions.
STAT
JUNE 24, 2024
On Tuesday, shares of Grail, the liquid biopsy company that hopes that its test, Galleri, will be widely used to screen for cancer, will become a publicly traded stock (with the ticker GRAL) that any investor can buy or sell on the Nasdaq. That will, in a sense, end a long, strange trip that has taken a decade. Grail was spun out by the DNA sequencing giant Illumina in 2015.
Fierce Healthcare
JUNE 24, 2024
UnitedHealthcare is betting big on its Surest unit as the insurer releases new data on where the plan has seen success in the past several years. | UnitedHealthcare is betting big on its Surest unit as the insurer releases new data on where the plan has seen success in the past several years.
STAT
JUNE 24, 2024
The results of a randomized controlled trial published Monday showed oral ketamine tablets were safe and effective for patients with treatment-resistant depression — the latest attempt by researchers to rigorously evaluate psychedelic drugs’ role in treating conditions like depression, anxiety and post-traumatic stress disorder. In the Phase 2 trial, the results of which were detailed in Nature Medicine , patients who took extended release ketamine tablets at an 180mg dosage twice
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
JUNE 24, 2024
Compared to placebo, nicotinamide riboside significantly improved the 6-minute walking capabilities in patients with decreased endurance and muscle function due to peripheral artery disease.
Fierce Healthcare
JUNE 24, 2024
Digital health company Sharecare has agreed to be acquired by private equity firm Altaris for $1.43 in cash per share, or about $518 million. | Digital health company Sharecare has agreed to be acquired by private equity firm Altaris for $1.43 in cash per share, or about $518 million.
pharmaphorum
JUNE 24, 2024
Bristol-Myers Squibb’s KRAS inhibitor Krazati has been approved for a second indication, colorectal cancer
STAT
JUNE 24, 2024
New research shows that, in spite of recommendations discouraging use of aspirin in primary prevention of cardiovascular disease among older adults, nearly a third of adults 60 years and older are still using it for this very purpose. The study , published on Monday in Annals of Internal Medicine, found that 18.5 million adults 60 and older without cardiovascular disease reported using preventative aspirin in 2021.
pharmaphorum
JUNE 24, 2024
Fenofibrate, a decades-old drug used to lower cholesterol levels, has been shown to reduce the progression of diabetic retinopathy in a large-scale trial.
Fierce Pharma
JUNE 24, 2024
After losing round one of its respiratory syncytial virus (RSV) vaccine bout with GSK, Pfizer is rallying. | After losing round one of its respiratory syncytial virus (RSV) vaccine bout with GSK, Pfizer is rallying. And what better way to do it than to win a major contract in your rival’s home country? The U.K. government has selected Pfizer to supply 5 million doses of its RSV shot Abrysvo over the next two years.
pharmaphorum
JUNE 24, 2024
Alnylam shares spike after vutrisiran aces HELIOS-B trial in ATTR-cardiomyopathy, setting up regulatory filings
STAT
JUNE 24, 2024
VALLETTA, Malta — The most sweeping corruption trial in the history of this Mediterranean country kicked off with a former prime minister and a host of top government officials parading through a phalanx of police into a courthouse. Hundreds of onlookers crammed narrow cobblestone streets, some screaming of their distrust in the government and disdain for the men who allegedly used their power to line their pockets.
pharmaphorum
JUNE 24, 2024
Novo Nordisk boosts manufacturing capacity for GLP-1 drugs again, unveiling a $4.
Pharmaceutical Technology
JUNE 24, 2024
The osteoporosis market is expected to grow at a compound annual growth rate of 5.4% from 2023 to 2032, reaching $17.9bn across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) by the end of this forecast period, according to leading data and analytics company GlobalData’s recent report: Osteoporosis: Seven-Market Drug Forecast and Market Analysis.
The Checkup by Singlecare
JUNE 24, 2024
If you have recurring back or neck pain or are dealing with an acute muscle spasm, over-the-counter pain medications, like ibuprofen , can offer much-needed relief. When those treatments still aren’t taking the edge off, your healthcare provider might prescribe something stronger, such as cyclobenzaprine. Also known by the brand name Flexeril, this medication is FDA approved to treat muscle spasms associated with painful musculoskeletal conditions.
Pharmaceutical Commerce
JUNE 24, 2024
The latest news for pharma industry insiders.
pharmaphorum
JUNE 24, 2024
Daiichi Sankyo has a second approval in Japan for Ezharmia, its first-in-class dual EZH1 and EZH2 inhibitor, as a treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL).Ezharmia (valemetostat tosylate) remains the first and only drug in the class to be approved for marketing around the world, having been cleared in Japan in 2022 for relapsed or refractory adult T-cell leukaemia/lymphoma (ATL).
Pharmaceutical Commerce
JUNE 24, 2024
A study examines the economical validity of using this therapy as a treatment for unresectable stage III non–small cell lung cancer.
Fierce Healthcare
JUNE 24, 2024
The Supreme Court will not hear a legal challenge to the nearly $2.7 billion Blue Cross Blue Shield settlement. | The Supreme Court will not hear a legal challenge to the nearly $2.7 billion Blue Cross Blue Shield settlement.
Expert insights. Personalized for you.
267 
Let's personalize your content